State Council Signals Property Stabilization; Three Innovative Drug BD Deals Closed in a Single Day
nashnova research
On September 29 China's property and innovative-drug sectors both rallied against the broader market — property ETFs jumped over 6% while three out-licensing deals worth a combined $66 billion-plus in potential value closed in a single day, firing the starting gun on Q4's two key capital-rotation trades.
What did the State Council actually say, and why did property stocks react instantly?
The State Council's executive meeting on September 28 pledged to roll out "practical and effective" incremental policies to stabilize the housing market. This means → Beijing has shifted from verbal reassurance to preparing concrete measures.
The same day, four Shanghai municipal agencies jointly issued a new housing policy covering pre-sale regulation, existing-home sales, lead-bank financing, and land supply. In plain terms = the central government set the tone; a tier-one city moved first — Shanghai is the test bed.
Property ETF Hwabao (159707.SZ) closed up 6.53%; Real Estate ETF Yinhua (159768.SZ) rose 6.40%; Real Estate ETF Huaxia (515060.SH) gained 4.52%.
What are brokerages saying about the property outlook?
CITIC Securities (China) argues the "8·28" housing reform is reshaping the sector's institutional framework, though city-level and company-level divergence will persist — it remains bullish on quality developers.
Founder Securities notes that resale transactions in 20 key cities have posted double-digit year-on-year growth for four consecutive weeks, confirming a visible recovery trend. This means → transaction data is already validating policy impact — this is not a pure expectations trade.
What are the three BD deals?
Hengrui Medicine out-licensed ex-Greater China global rights to its oral once-weekly GLP-1/GIP dual-receptor agonist — a weight-loss pill taken once a week — for up to $2.6 billion, with a $300 million upfront payment.
AstraZeneca made a $2 billion strategic investment in Summit Therapeutics to advance Akeso's ivonescimab combination therapy — a bispecific-antibody immunotherapy — in clinical trials.
Shanghai Simcere Zaiming (SPR Pharma) licensed its pre-clinical oral KRAS G12D inhibitor — a drug targeting a specific cancer-gene mutation — to a multinational, with a $400 million upfront payment, setting a new global record for pre-clinical asset upfront fees.
Why does it matter that three deals landed on the same day?
Each deal exceeds $2 billion in potential value, spanning oral weight-loss, bispecific antibodies, and the RAS oncology target — three of the hottest therapeutic pipelines globally. In plain terms = multinationals placed real money on three separate technology bets in a single day, signaling they are systematically sweeping Chinese innovative-drug pipelines, not betting on one target.
Innovative Drug ETF Yinhua (159567.SZ) rose 3.07%; Hang Seng Innovative Drug ETF (520500.SH) gained 3.01%; Southbound Innovative Drug ETF (159570.SZ) added 2.76%.
This reflects a market repricing of China's biopharma sector as it transitions from "telling the story" to "delivering data and deals."
Can innovative-drug fundamentals actually support this rally?
Industrial Securities sees "innovation + globalization" as the core pharma theme for 2026.
Kaiyuan Securities provides the hard numbers: in H1 2026, 39 listed Chinese biotechs posted combined revenue growth of 33.81% year-on-year, with aggregate net profit swinging from loss to RMB 8.119 billion in the black. This means → the industry has crossed the break-even line as a whole — BD deals are no longer money-losing firms selling pipelines to survive, but profitable companies pursuing proactive globalization.
What should investors watch in Q4?
The property trade hinges on the pace of incremental policy rollout — the State Council has set the direction, but the density and strength of follow-through measures will determine whether this is a one-day spike or a sustained trend.
The biopharma trade hinges on whether BD deal flow continues — if three deals in one day is a peak rather than a new normal, the sector's valuation re-rating stalls.
In plain terms = both themes have heard the starting gun, but how far they run depends on the coming weeks' policy cadence and deal frequency.
市场有风险，内容仅供研究参考，不构成投资建议。